Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.

Area of Science:

• Oncology
• Pharmacology

Background:

• The combination of ifosfamide and irinotecan is being investigated for potential synergistic anti-cancer effects.
• Phase I clinical trials are crucial for determining safe dosage and identifying dose-limiting toxicities of novel drug combinations.

Purpose of the Study:

• To conduct a dose-finding study of the ifosfamide and irinotecan combination.
• To evaluate the safety and preliminary efficacy of this combination in patients.

Main Methods:

• A dose-escalation Phase I clinical trial design was employed.
• Patients received escalating doses of ifosfamide and irinotecan.
• Toxicity was monitored to identify dose-limiting events.
• Tumor response was assessed to evaluate preliminary activity.

Main Results:

• The study is ongoing, with dose escalation continuing beyond nine levels.
• No major dose-limiting toxicities have been identified to date.
• The primary observed toxicity is mild gastrointestinal issues (nausea, vomiting, diarrhea), manageable with supportive care.
• Stable disease was observed in some patients, indicating potential anti-cancer activity.

Conclusions:

• The combination of ifosfamide and irinotecan appears to have a manageable toxicity profile in this ongoing Phase I study.
• Preliminary evidence suggests some anti-cancer activity for this drug combination.
• Further studies are needed to establish the optimal dose and confirm efficacy.